ConductScience.org, home

Paper42936601PubMed

CAR-T-cell therapy for autoimmune neurologic diseases.

Zhao Y and 6 others. Front Immunol, 2026.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. CAR-T-cell therapy for autoimmune neurologic diseases. Papers, record 42936601. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42936601

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CAR-T-cell therapy for autoimmune neurologic diseases.
Journal
Front Immunol
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-10-28

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhao YYunhan
2Ding YYunyu
3Tang CCongfeng
4Wei ZZhengrong
5Fan YYuqing
6Hu XXianhui
7Yi JJilong

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Autoimmune Diseases of the Nervous SystemMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
T-LymphocytesMajor topic
Humans
Animals
B-Lymphocytes

Source PubMed

Download CSV of topics

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123290630Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.Lancet Neurol2013https://conductscience.org/library/papers/23290630PubMed
239874224CD19-CAR T-cell therapy induces deep tissue depletion of B cells.Ann Rheum Dis2025https://conductscience.org/library/papers/39874224PubMed
341101309Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis.Cell2025https://conductscience.org/library/papers/41101309PubMed
429972754Chimeric Antigen Receptor Therapy.N Engl J Med2018https://conductscience.org/library/papers/29972754PubMed
533324003B cell depletion therapies in autoimmune disease: advances and mechanistic insights.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33324003PubMed
640706586Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis.Med2025https://conductscience.org/library/papers/40706586PubMed
736070711Neuromyelitis Optica Spectrum Disorder.N Engl J Med2022https://conductscience.org/library/papers/36070711PubMed
826906964A clinical approach to diagnosis of autoimmune encephalitis.Lancet Neurol2016https://conductscience.org/library/papers/26906964PubMed
930592986ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/30592986PubMed
1036198831Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.Nat Rev Rheumatol2022https://conductscience.org/library/papers/36198831PubMed
1131050279Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.N Engl J Med2019https://conductscience.org/library/papers/31050279PubMed
1238697115Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells.Neuron2024https://conductscience.org/library/papers/38697115PubMed
1336109639Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.Nat Med2022https://conductscience.org/library/papers/36109639PubMed
1439106426CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year.Neurol Neuroimmunol Neuroinflamm2024https://conductscience.org/library/papers/39106426PubMed
1536706773Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.Lancet Neurol2023https://conductscience.org/library/papers/36706773PubMed
1641514038BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.Nat Med2026https://conductscience.org/library/papers/41514038PubMed
1735025605Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.Science2022https://conductscience.org/library/papers/35025605PubMed
1837353278Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.Lancet Neurol2023https://conductscience.org/library/papers/37353278PubMed
1937977704Anti-CD19 CAR T cells for refractory myasthenia gravis.Lancet Neurol2023https://conductscience.org/library/papers/37977704PubMed
2021298406Anti-NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders.Curr Treat Options Neurol2011https://conductscience.org/library/papers/21298406PubMed

See all 51 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42936601

GET https://conductscience.org/api/papers/v1/42936601/references?page=2